Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why
We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...
pulmonologyadvisor4h
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Joe Scott on MSN5h
How The COVID-19 Vaccine Could Lead To A Cure For Cancer ¦ Answers With Joe
The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19. They have the ability to help the body fight a multitude of diseases, from ...
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?
Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...
Why Moderna (MRNA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
Your phone is a breeding ground for fecal bacteria. This is how to keep it clean and prevent getting sick
“People's phones are out when urinating and defecating, exposing the phones to bacteria,” says Dr. Suraj Saggar, chief of ...
Hosted on MSN19h
Goldman Sachs Downgrades Moderna (MRNA)
Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...
Officials: Bird flu spreading in state, but cases still low in Central Mass.
The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
KDRV1d
Dr. Sanjay Gupta: Benefits of vaccines are a matter of fact
I have started, scratched out and even abandoned the writing of this essay. I couldn’t do it. It wasn’t there. Didn’t feel it ...
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...
Moderna stock drops as Goldman Sachs cuts rating
Moderna (NASDAQ: MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...